Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow Growth (3y) (2020 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.14 Bn | 5.61 Bn | 220.03 Mn | -34.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.75% |
| Mar 31, 2026 | 37.13% |
| Dec 31, 2025 | 44.11% |
| Sep 30, 2025 | -30.27% |
| Jun 30, 2025 | 4.05% |
| Mar 31, 2025 | 23.53% |
| Dec 31, 2024 | 48.47% |
| Sep 30, 2024 | -27.77% |
| Jun 30, 2024 | -42.10% |
| Mar 31, 2024 | 78.56% |
| Dec 31, 2023 | -32.96% |
| Sep 30, 2023 | 28.87% |
| Jun 30, 2023 | 23.12% |
| Mar 31, 2023 | -39.40% |
| Dec 31, 2022 | -34.34% |
| Sep 30, 2022 | 98.47% |
| Jun 30, 2022 | 455.24% |
| Mar 31, 2022 | -96.20% |
| Dec 31, 2021 | -215.06% |
| Sep 30, 2021 | 28.10% |